Achema middle east

Dainippon wins manufacturing approval for sleep inducing therapy in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Continuous Manufacturing Equipment: Adoption Barriers and Industry Readiness

While continuous manufacturing offers efficiency and quality benefits, high capital costs and technical barriers like PAT integration, feeder accuracy, and RTD modeling slow its widespread adoption in pharma.

Sustainable Laboratory Equipment Innovations Supporting Green Pharma Initiatives

As the pharmaceutical industry strives for carbon neutrality, the laboratory has become a focal point for sustainability efforts. This article highlights the latest innovations in eco-friendly equipment, from ultra-low temperature freezers to solvent recovery systems, demonstrating how green technology can reduce environmental impact without compromising scientific rigor.

Largest Vaccine Manufacturing Facility in Egypt Launched

Egypt has gone on to mark quite a prominent...
- Advertisement -

Dainippon Sumitomo Pharma has obtained manufacturing and marketing approval for Zolpidem tartrate tablets 5mg/10mg [DSP] from the Ministry of Health, Labour and Welfare in Japan. Zolpidem tartrate tablets 5mg/10mg [DSP] are film-coated tablets containing 5mg or 10mg of zolpidem tartrate, with a score line on one side, which are indicated for the treatment of Insomnia. The usual adult dose is once daily 5 to 10mg of zolpidem tartrate administered orally immediately before bedtime, the company said. The initial dose for elderly patients is from 5mg once daily and may be adjusted depending on age, symptoms, disease, and should not exceed 10mg once daily.

Latest stories

Related stories

Continuous Manufacturing Equipment: Adoption Barriers and Industry Readiness

While continuous manufacturing offers efficiency and quality benefits, high capital costs and technical barriers like PAT integration, feeder accuracy, and RTD modeling slow its widespread adoption in pharma.

Sustainable Laboratory Equipment Innovations Supporting Green Pharma Initiatives

As the pharmaceutical industry strives for carbon neutrality, the laboratory has become a focal point for sustainability efforts. This article highlights the latest innovations in eco-friendly equipment, from ultra-low temperature freezers to solvent recovery systems, demonstrating how green technology can reduce environmental impact without compromising scientific rigor.

Largest Vaccine Manufacturing Facility in Egypt Launched

Egypt has gone on to mark quite a prominent...

UK Plans to Produce Cancer Treatment from Nuclear Waste

Bicycle Therapeutics has entered into a 15-year agreement with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »